China's Biologics Surge
China's rise in biopharmaceuticals is now a firm reality. Driven by focused government policies and faster regulatory processes, China has advanced rapidly over the past seven years, becoming a key part of global supply chains. By 2023, biologics made up about 42% of its new drug approvals, up from just 9% in 2015. China approved 83 new drugs in 2024, significantly more than the US's 50, and has narrowed the gap in drug approval times with Western markets. This strong government backing and quick market entry give Chinese firms a major competitive advantage, securing over half of recent project mandates from US biotech companies.
India's Biologics Struggle
For Indian pharmaceutical companies, the global biologics market, expected to reach $232 billion by 2034, presents a harder path than its earlier success in generics. Unlike generics, which relied on low costs and large-scale manufacturing, biologics require advanced research, complex manufacturing, and skilled talent. These demands create significant entry barriers and financial risks that India is still working to overcome. Experts say India must move from 'cost leadership' to 'capability leadership.' However, lasting gaps in key areas like advanced cell line engineering, strong intellectual property plans, and effective access to the US market continue to slow this crucial evolution. The difference in government support and regulatory speed between China and India makes it difficult for Indian firms to grow and compete effectively.
Comparing China and India in Biologics
Key players in the biologics field show differing paths. WuXi Biologics, a major Chinese CDMO, had a market capitalization of about $129.75 billion as of March 31, 2026. Its P/E ratio, recently around 23.83 (TTM) as of March 2026, indicates strong investor confidence. In contrast, Indian companies like Biocon and Dr. Reddy's Laboratories show varied valuations. Biocon's P/E ratio is high at approximately 78.28 (TTM), and its market cap reached about $584.07 billion by March 30, 2026, signaling growth expectations but also potentially high valuations. Dr. Reddy's Laboratories has a more moderate P/E ratio, around 18.41 as of March 2026. The global biosimilars market is projected to reach $1.3 trillion by 2032, with India's biosimilar exports expected to grow from $0.8 billion to $4.2 billion by 2030. Yet, China's aggressive push into novel biologics, fast approval cycles, and extensive R&D investment pose a significant challenge to India's more gradual approach.
India's Hurdles: Weaknesses and Geopolitics
The path ahead for India's biologics sector faces many risks. The country needs to address key weaknesses in advanced cell line engineering, a vital component for complex biologics, and strengthen its legal and IP strategy for global competition. Gaining robust market access in the US remains a major challenge, especially compared to China's faster regulatory pathways and strong government backing. Biologics manufacturing is complex and involves trade secrets, creating high entry barriers that can't be overcome by cost alone. Geopolitical shifts, like concerns over the US Biosecure Act and a broader 'China Plus One' strategy, are pushing Western clients to look for other CDMO partners. While this offers India a chance to be a reliable alternative, it also brings its own complexities and requires significant investment beyond its traditional strengths in generic production. Failure to close these structural gaps risks India being sidelined in the next wave of global drug innovation, despite the vast market potential.
India's Path Forward
The Indian biopharmaceutical sector is at a crucial moment, needing a shift to innovation platforms, AI, and strong R&D to climb the value chain. Suresh Subramanian, National Lifesciences Leader at EY-Parthenon India, noted that future success will depend on combining drug discovery, AI, and manufacturing into reliable, repeatable platforms, rather than relying only on scientific breakthroughs. The industry must move from unique products to versatile engines, especially as it focuses on large molecules and next-generation therapies. Achieving this requires substantial investment and strategic alignment, or India risks becoming a minor player in the global biologics arena.